Yuanyuan Wei, PhD, a postdoctoral scholar in the UCLA Department of Neurology, has been selected as one of ten recipients nationwide of the 2026 WHAM Edge Award. The $25,000 award will advance her research combining artificial intelligence (AI) with experimental neuroscience to discover potential treatments for Alzheimer's disease.

Her research focuses on tau, a protein that accumulates abnormally in Alzheimer's disease. Wei developed TauSeer, an AI tool that screened 53 million molecules to identify promising drug candidates. Rather than relying on computational predictions alone, the team tests these candidates in neurons exposed to tau isolated from Alzheimer's patients. The experimental results are then used to improve the AI model, creating a continuous cycle of prediction, testing, and refinement. So far, 22 promising compounds have reduced abnormal tau buildup in neurons by more than 30%.

With support from WHAM, Wei will extend this approach to investigate whether potential treatments work differently in female and male neurons. Since nearly two-thirds of Americans living with Alzheimer's are women, incorporating biological sex earlier in drug discovery could help researchers make better decisions about which compounds to advance.

The award marks an important milestone in a growing interdisciplinary collaboration at UCLA.

Trained in precision instrumentation at Tsinghua University and biomedical engineering at The Chinese University of Hong Kong, Wei joined the laboratory of Chao Peng, PhD, in November 2024. She brought extensive engineering experience but was new to Alzheimer's disease research. Peng encouraged her to apply those skills to challenging questions in neurodegeneration. Co-mentored by Peng and Wei Wang, PhD, Leonard Kleinrock Chair Professor in computer science, she began bridging AI development with disease-relevant neuronal experiments. In May 2025, the project received its first funding through the Mary S. Easton Center's Engineering Solutions to Dementia initiative.

"AI allows us to explore drug candidates at a scale that was previously impossible," said Peng. "But computational predictions must be grounded in rigorous biological experiments. Bringing these strengths together is where we see real opportunities to accelerate Alzheimer's drug discovery."

The team's progress has since earned wider recognition. In 2026, their work won first place in neuroscience at UCLA's LABEST Pearl Cohen Scientific Poster Competition. Wei also received a BrightFocus Foundation/Alzheimer's Los Angeles Bold Ideas Award, one of two awards supporting Southern California researchers through the partnership, and a BrightFocus Alzheimer's FastTrack Workshop travel award. BrightFocus subsequently nominated her for the WHAM Edge Award.

"When I joined Dr. Peng's lab, I had a strong engineering background but so much to learn about Alzheimer's disease," Wei said. "Dr. Peng gave me that opportunity, and my co-mentor Dr. Wang, our collaborators, lab members, and students have helped me grow tremendously. I'm deeply grateful to the Easton Center and BrightFocus Foundation for supporting our research, and to BrightFocus for nominating me for WHAM. None of this would have been possible without such a generous and collaborative team."

The WHAM award supports the next chapter of this collaboration: bringing AI and neuroscience together to discover better therapeutic possibilities for Alzheimer's disease.